FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-FLT3-ITD-AML-RR |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-AML |
| Sources | SRC-ADMIRAL-PERL-2019 SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-FLT3-ITD |
|---|---|
| Variante | internal tandem duplication (relapsed/refractory AML) |
| Maladie | DIS-AML |
| Niveau ESCAT | IA |
| Combinaisons recommandées | gilteritinib monotherapy (2L bridge to allo-SCT), gilteritinib + venetoclax + azacitidine (off-label intensification, trial) |
| Résumé des faits | FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (ADMIRAL, Perl NEJM 2019 — OS 9.3 vs 5.6 mo, HR 0.64). Gilteritinib is preferred 2L for FLT3-mutant R/R AML and is a bridge to allo-SCT. Quizartinib also active R/R (QuANTUM-R) but FDA label is 1L only (R/R label withdrawn). |
Notes
ESCAT IA. OncoKB Level 1. Resistance: F691L gatekeeper, D835 TKD emerge under gilteritinib pressure — see BMA-FLT3-D835-AML-RR and BMA-FLT3-F691L-AML for next-step considerations. Distinguish from BMA-FLT3-ITD-AML which covers 1L.
Utilisé par
No reverse references found in the YAML corpus.